Tags : Arvinas

Bayer Signs a Research and Development Collaboration with Arvinas for

Shots: Arvinas to get ~$60M including upfront, equity investments, R&D funds and $685M milestones and royalties on sales of products. Bayer to get rights for the therapies developed in collaboration using Arvinas’s PROTAC Technology The focus of the collaboration is to develop therapies using Arvinas’ PROTAC protein degrader technology in cardiovascular, oncology, and gynecological disorders […]Read More